In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis
about
sameAs
Periprosthetic bone loss: diagnostic and therapeutic approachesIn vivo imaging of particle-induced inflammation and osteolysis in the calvariae of NFκB/luciferase transgenic miceInhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritisRemodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy.Emerging ideas: can erythromycin reduce the risk of aseptic loosening?Infrared assessment of bone quality: a reviewAseptic loosening.Role of polyethylene particles in peri-prosthetic osteolysis: A review.Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapies.Clinical development of anti-RANKL therapyComparison of the roles of IL-1, IL-6, and TNFalpha in cell culture and murine models of aseptic loosening.Combination gene therapy targeting on interleukin-1β and RANKL for wear debris-induced aseptic loosening.Mechanisms of bone loss in rheumatoid arthritis.Anti-oxidation treatment of ultra high molecular weight polyethylene components to decrease periprosthetic osteolysis: evaluation of osteolytic and osteogenic properties of wear debris particles in a murine calvaria model.The central role of wear debris in periprosthetic osteolysis.Mouse anti-RANKL antibody delays oral wound healing and increases TRAP-positive mononuclear cells in bone marrow.Antioxidant impregnated ultra-high molecular weight polyethylene wear debris particles display increased bone remodeling and a superior osteogenic:osteolytic profile vs. conventional UHMWPE particles in a murine calvaria model.Genetic susceptibility to hip arthroplasty failure--association with the RANK/OPG pathwayMechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets.Alternative macrophage activation in periprosthetic osteolysis.Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT.Therapeutic potentials of naringin on polymethylmethacrylate induced osteoclastogenesis and osteolysis, in vitro and in vivo assessments.RANKL inhibition for the management of patients with benign metabolic bone disorders.Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.Osteolysis around total knee arthroplasty: a review of pathogenetic mechanisms.Periprosthetic osteolysis: genetics, mechanisms and potential therapeutic interventions.Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib.Orthopaedic implant failure: aseptic implant loosening--the contribution and future challenges of mouse models in translational research.Protection against titanium particle-induced osteoclastogenesis by cyclooxygenase-2 selective inhibitor.Pressuromodulation at the cell membrane as the basis for small molecule hormone and peptide regulation of cellular and nuclear functionExtracellular matrix degradation and tissue remodeling in periprosthetic loosening and osteolysis: focus on matrix metalloproteinases, their endogenous tissue inhibitors, and the proteasome.Substance P enhanced titanium particles-induced RANKL expression in fibroblasts from periprosthetic membrane.Osteopontin deficiency impairs wear debris-induced osteolysis via regulation of cytokine secretion from murine macrophages.Wear particles enhance autophagy through up-regulation of CD147 to promote osteoclastogenesis
P2860
Q27024847-8FADFD49-C5EC-4FE2-8B9D-879B4DDB023FQ28383687-6AD973A7-ECFA-408C-B4D8-F0FE946E59DCQ33606922-19D0FCB5-1F85-4D29-B8EB-B788A0025A71Q34345061-C0B4D40D-D5F6-4B53-93E8-6CAEEE203911Q35078775-95D34DBD-B1B2-46C7-AE30-23AA4E7C7FF5Q35078785-4FDF0CEF-A066-4E75-9C1A-9A29BF521C30Q35629551-DB52E324-87C8-4AA6-A09D-4006FA264DF4Q35825373-FE00C811-1C8B-4DF5-9D17-7FDECA42C5A9Q35901087-6BE01BEF-7024-4A69-B58F-4FAD8777BBD6Q35901092-3A3E92A5-693C-4A7F-B061-56C6B127411EQ35908576-3A6405C6-AF81-4BAE-905A-2F8417B7519DQ35951712-3E1A7858-AC3B-450A-8D85-1970B030FED8Q36618009-E6EE4752-AD94-4291-86C1-80FC1D880D5DQ36795335-C23A5DF6-A94C-48D1-9223-6B548C0912CEQ36796472-91C1D9C1-EB6E-425E-B970-62FE2AD9261DQ36823728-F45AB329-B19F-4AB8-A4D8-74BDAABC0A6FQ36828591-62C509A8-FAC0-4801-AFE6-F37B54A671AFQ36867041-96A5059F-0DAE-4C6F-97D1-493CDD5FBAD8Q37106639-E98BC419-A0D9-414A-B4ED-EFF60276DA41Q37118773-B07C2A8A-DB47-4023-8084-31DBF8D37270Q37342578-C2FBAC39-54CA-4865-8D7C-F3C0FAAC011BQ37396554-E0296CD2-150B-4699-9C38-34397E0ADF93Q37532561-2E80540A-1B49-4769-AE48-25B76B57AE4AQ37579579-61EB3D15-4105-45D9-B821-0B07A12392EAQ37730881-7D197295-EE87-47B6-9088-CC494B5BCFD2Q38044786-18DEDDC4-16CA-494D-8FAD-A1D127E4FF8AQ38183262-0F4414CA-D695-4678-A5AF-CCB5615F6B23Q38211743-68C30A83-4D97-4836-99D0-08AF2F16EAB1Q39474660-3FF5D75B-4117-48F3-BA68-F7DB03537FA4Q42153567-9FBD88F6-4034-458F-8B07-432F1BB8EF29Q42755979-718DCAEC-DFB3-412B-8D54-2BDA06F364BEQ43573612-41894502-90FF-43E8-BE33-1FC2A73E54DCQ44499807-ABB3663F-D56C-4C11-BB60-981B1BBC29CEQ58805042-C6D2D73B-86FF-4638-93FC-66DD882B16F3
P2860
In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
In vivo RANK signaling blockad ...... ithout inhibiting osteogenesis
@ast
In vivo RANK signaling blockad ...... ithout inhibiting osteogenesis
@en
In vivo RANK signaling blockad ...... ithout inhibiting osteogenesis
@nl
type
label
In vivo RANK signaling blockad ...... ithout inhibiting osteogenesis
@ast
In vivo RANK signaling blockad ...... ithout inhibiting osteogenesis
@en
In vivo RANK signaling blockad ...... ithout inhibiting osteogenesis
@nl
prefLabel
In vivo RANK signaling blockad ...... ithout inhibiting osteogenesis
@ast
In vivo RANK signaling blockad ...... ithout inhibiting osteogenesis
@en
In vivo RANK signaling blockad ...... ithout inhibiting osteogenesis
@nl
P2093
P1476
In vivo RANK signaling blockad ...... ithout inhibiting osteogenesis
@en
P2093
Adele L Boskey
Brendan F Boyce
Dirk Anderson
Edward M Schwarz
Eleftherios P Paschalis
J Edward Puzas
Lianping Xing
Lisa M Childs
Randy N Rosier
Regis J O'Keefe
P356
10.1359/JBMR.2002.17.2.192
P407
P577
2002-02-01T00:00:00Z